PAVmed (NASDAQ:PAVM – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $0.02 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
PAVmed Trading Up 15.7 %
PAVM stock opened at $0.76 on Tuesday. The firm has a 50-day moving average of $0.68 and a two-hundred day moving average of $0.92. The firm has a market capitalization of $8.45 million, a PE ratio of -0.18 and a beta of 1.19. PAVmed has a one year low of $0.57 and a one year high of $2.84.
Analysts Set New Price Targets
Separately, Ascendiant Capital Markets dropped their price target on PAVmed from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th.
PAVmed Company Profile
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Featured Stories
- Five stocks we like better than PAVmed
- How Technical Indicators Can Help You Find Oversold Stocks
- Can TikTok Stock Picks Really Make You Rich?
- What is the Australian Securities Exchange (ASX)
- The “Quality” Rotation: Back to Basics Investing
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.